Mimedx (MDXG) Return on Capital Employed (2011 - 2026)
Mimedx (MDXG) reported Return on Capital Employed of 14.08% for Q1 2026, down 993.0% on a YoY basis from 1.58% in Q1 2025, and down 41.24% sequentially from 23.97% in Q4 2025.
Mimedx (MDXG) Return on Capital Employed (2011 - 2026) Analysis & Trends
Mimedx (MDXG) has 15 years of Return on Capital Employed data on file, last reported at 14.08% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 993.0% year-over-year to 14.08%; the trailing twelve-month figure through Mar 2026 stood at 14.08% (down 993.0% YoY), and the FY2025 full-year result was 26.73%, down 186.0% from the prior year.
- Return on Capital Employed fell to 14.08% in Q1 2026, from 23.97% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 34.03% in Q2 2024 to a low of 19.82% in Q3 2022.
- A 5-year average of 13.24% and a median of 21.78% in 2025 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 4350 bps in 2023 and slumped 1544 bps in 2025, its largest moves.
- Tracing MDXG's Return on Capital Employed over 5 years: stood at 11.46% in 2022, then surged by 293 bps to 22.09% in 2023, then gained by 28 bps to 28.26% in 2024, then dropped by 15 bps to 23.97% in 2025, then sank by 41 bps to 14.08% in 2026.
- Business Quant data shows MDXG's Return on Capital Employed at 14.08% in Q1 2026, 23.97% in Q4 2025, and 21.78% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Mimedx | 615.09 Mn | 455.31 Mn | 41.62 Mn | 14.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.08% |
| Dec 31, 2025 | 23.97% |
| Sep 30, 2025 | 21.78% |
| Jun 30, 2025 | 18.59% |
| Mar 31, 2025 | 24.01% |
| Dec 31, 2024 | 28.26% |
| Sep 30, 2024 | 32.45% |
| Jun 30, 2024 | 34.03% |
| Mar 31, 2024 | 26.92% |
| Dec 31, 2023 | 22.09% |
| Sep 30, 2023 | 23.68% |
| Jun 30, 2023 | 11.51% |
| Mar 31, 2023 | -4.47% |
| Dec 31, 2022 | -11.46% |
| Sep 30, 2022 | -19.82% |
| Jun 30, 2022 | -13.93% |
| Mar 31, 2022 | -6.57% |
| Dec 31, 2021 | -4.97% |
| Sep 30, 2021 | -17.19% |
| Jun 30, 2021 | -23.89% |